Table 1.
Clinical Trials listed on clinicaltrials.gov for Parkinson’s disease.
| No | Disease | Sponsor | Cell type | Route | Cell dose | Plannedparticipants | Year | Phase | Clinical trial # |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Parkinson disease | Craig Van Horne | Autologous peripheral nerve graft | Implanted to substantia nigra | Not mentioned | 8 | 2012 | na | NCT01833364 |
| 2 | Parkinson disease | Craig Van Horne | Autologous peripheral nerve graft | Implanted to substantia nigra | Not mentioned | 70 | 2015 | 1 | NCT02369003 |
| 3 | Parkinson disease | University of Jordan | Allogenic WJSC and its derived NSC | MSC (IV, IT), NSCs (IT) | MSC for iv (120-180 M), MSC for IT (240-260 M), NSC (24-36 MM) | 10 | 2018 | 1/2 | NCT03684122 |
| 4 | Advanced Parkinson disease | BlueRock Therapeutics | ESC-derived dopamine neurons (MSK-DA01) | Surgical transplanted into putamen | Not mentioned | 12 | 2021 | 1 | NCT04802733 |
| 5 | Parkinson disease | The Foundation for Orthopaedics and Regenerative Medicine | Allogenic UC-MSC | IV | 100M | 20 | 2011 | 1 | NCT05152394 |
| 6 | Neurodegenerative disease | Elliot Lander | Autologous adipose-derived stromal vascular fraction | IV, intra-articular, and soft-tissue injections. | Not mentioned | 3000 | 2013 | na | NCT01953523 |
| 7 | Stroke/TBI/Parkinson/ALS/Alzheimer/Dementia | MD Stem Cells | Autologous BMSC | IV and intranasal | Not mentioned | 500 | 2016 | na | NCT02795052 |
| 8 | TBI/Alzheimer’s/Dementia/Parkinson-Dementia/Late Encephalopathy | MD Stem Cells | Autologous BMSC | iv and intranasal | Not mentioned | 100 | 2018 | na | NCT03724136 |
| 9 | Parkinson disease | The University of Texas Health Science Center | Allogenic BM MSC | IV | 1,3,6, and 10 M/kg | 20 | 2017 | 1 | NCT02611167 |
| 10 | Parkinson disease | The University of Texas Health Science Center | Allogenic BM MSC | IV | 20 and 30 M/KG | 45 | 2020 | 2a | NCT04506073 |
| 11 | Parkinson disease | Belarusian Medical Academy of Post-Graduate Education | Autologous BM MSC | IV and intranasal | IV(0.5-2 M/kg), intranasal (5-12.6M) + IV (10-50 M) | 50 | 2017 | 2,3 | NCT04146519 |
| 12 | Parkinson disease | Hebei Newtherapy Bio-Pharma Technology Co., Ltd | MSC | IV | 10-20 M | 20 | 2018 | 1 | NCT03550183 |
| 13 | Multiple system atrophy/ Parkinsonism | Indonesia University | Autologous adipose MSC, allogeneic UC MSC | IT | Adipose MSC (100M), uc MSC (100M) | 15 | 2020 | na | NCT04876326 |
| 14 | Parkinson disease | Shanghai East Hospital | Human amniotic epithelial stem cells | Stereotactic implantation into lateral ventricle | 50 M | 3 | 2020 | 1 | NCT04414813 |
| 15 | Parkinson disease | Shanghai East Hospital | Human amniotic epithelial stem cells | Stereotactic implantation into lateral ventricle | 50 M | 12 | 2022 | 1 | NCT05435755 |
| 16 | Parkinson disease | Hope Biosciences Stem Cell Research Foundation | Allogenic adipose-derived MSC (HB-adMSCs) | IV | Not mentioned | 60 | 2021 | 2 | NCT04995081 |
| 17 | Parkinson disease | Hope Biosciences Stem Cell Research Foundation | Autologous adipose-derived MSC (HB-adMSCs) | IV | Not mentioned | 24 | 2021 | 2 | NCT04928287 |
| 18 | Idiopathic Parkinson disease | Taiwan Mitochondrion Applied Technology Co., Ltd | Autologous adipose-derived MSC (Mitocell) | Stereotactic intrastriatal implantation | 60 M and 200M | 9 | 2022 | 1 | NCT05094011 |
Abbreviations: ALS, amyotrophic lateral sclerosis; BM-MSC, bone marrow mesenchymal stem cells; BMSC, bone marrow stem cells; IM, intramuscular; IT, intrathecal; IV, intravenous; M, million; na, not applicable TBI, traumatic brain injury; UC, umbilical cord.